Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Status:
Completed
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5
inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients